Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03484-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Abdul Qahar Khan Yasinzai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Bolan Medical College, Quetta, 83700, Pakistan. abdul.qahar.aqk@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, SEER Program. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy about 50% of PDAC are metastatic at presentation. In this study, we evaluated PDAC demographics, annual trend analysis, racial disparities, survival rate, and the role of different treatment modalities in localized and metastatic disease. METHODS: A total of 144,824 cases of PDAC were obtained from the SEER database from 2000 to 2018. RESULTS: The median age was 69 years, with a slightly higher incidence in males (52%) and 80% of all cases were white. Among cases with available data, 43% were grade III tumors and 57% were metastatic. The most common site of metastasis was the liver (15.7%). The annual incidence has increased steadily from 2000 to 2018. The overall observed (OS) 5-year survival rate was 4.4% (95% CI 4.3-4.6%), and 5 years cause-specific survival (CSS) was 5% (95% CI 5.1-5.4%). The 5-year survival with multimodal therapy (chemotherapy, surgery, and radiation) was 22% (95% CI 20.5-22.8%). 5-year CSS for the blacks was lower at 4.7% (95% CI 4.2-5.1%) compared to the whites at 5.3% (95% CI 5.1-5.4%). Multivariate analysis found male gender and black race associated with worse prognosis. Kaplan-Meier survival analysis found multimodal therapy to have the best outcomes in all three stages. CONCLUSION: PDAC is an aggressive malignancy with male gender and black race are associated with a poor prognosis. Surgery with chemoradiation was associated with the best overall survival. With steadily increasing rates of PDAC, improved treatment modalities are paramount to improving survival in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Bolan Medical College, Quetta, 83700, Pakistan. abdul.qahar.aqk@gmail.com.
- Department of Medicine, Bolan Medical College, Quetta, 83700, Pakistan.
- Medical College of Georgia, Augusta, GA, 30912, USA.
- Internal Medicine, Marshfield Medical Center, Marshfield, USA.
- Department of Oncology Developmental Therapeutics, Novant Health, Charlotte, NC, USA.
- Department of Surgery, San Joaquin General Hospital, French Camp, CA, 95231, USA.
Zitieren
APA
Yasinzai, A. Q. K., Tareen, B., Tracy, K., Jamil, N., Khan, M., Ullah, H., Raza, M., Khan, A. U., Arif, D., Waheed, A., Sidhwa, F., Misra, S., Karki, N. R., Karim, N. A., Cavalcante, L., & Ullah, A. (2024). Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03484-7
Vancouver
Yasinzai AQK, Tareen B, Tracy K, Jamil N, Khan M, Ullah H, et al. Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03484-7
BibTeX
@article{Yasinzai2024,
author = {Yasinzai, Abdul Qahar Khan and Tareen, Bisma and Tracy, Katharine and Jamil, Nimra and Khan, Marjan and Ullah, Hafeez and Raza, Muhammad and Khan, Amin Ullah and Arif, Dauod and Waheed, Abdul and Sidhwa, Feroze and Misra, Subhasis and Karki, Nabin Raj and Karim, Nagla Abdel and Cavalcante, Ludimila and Ullah, Asad},
title = {Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03484-7}
}
EUVIMED